Of patients identified as low risk by combined clinicopathological factors and ...
Median duration of recurrence-free survival was 61.1 months with nivolumab and ...
Overall melanoma risk lower for those who had received four or ...
Complete response rate was 37 percent, and post-hoc end point of ...
80 percent of adult patients with stage III/IV resectable melanoma remained ...
Machine learning algorithm has superior reproducibility and prognostic associations compared with ...
Patients belonging to haplogroup T exhibit unique nivolumab-resistant baseline peripheral CD8+ ...